Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8-Mediated Metabolism of Montelukast in Humans-Reference-Cited by-同舟云学术

Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8-Mediated Metabolism of Montelukast in Humans

Published:2017-12-23 Issue:3 Volume:104 Page:495-504
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Itkonen Matti K.¹,Tornio Aleksi¹,Filppula Anne M.¹²,Neuvonen Mikko¹,Neuvonen Pertti J.¹,Niemi Mikko¹,Backman Janne T.¹

Affiliation:

1. Department of Clinical Pharmacology; University of Helsinki and Helsinki University Hospital; Helsinki Finland

2. Uppsala Drug Optimization and Pharmaceutical Profiling Platform (UDOPP), Department of Pharmacy; Uppsala University; Uppsala Sweden

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cpt.947/fullpdf

Reference31 articles.

1. A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. Montelukast Asthma Study Group;Altman;J. Allergy Clin. Immunol.,1998

2. Leukotriene-receptor antagonists;Lipworth;Lancet,1999

3. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group;Reiss;Arch. Intern. Med.,1998

4. Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females;Cheng;Pharm. Res.,1996

5. Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile;Balani;Drug Metab. Dispos.,1997

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A genetic algorithm-based approach for the prediction of metabolic drug-drug interactions involving CYP2C8 or CYP2B6;Journal of Pharmacological and Toxicological Methods;2024-05

2. Interplay of UDP-Glucuronosyltransferase and CYP2C8 for CYP2C8 Mediated Drug Oxidation and Its Impact on Drug–Drug Interaction Produced by Standardized CYP2C8 Inhibitors, Clopidogrel and Gemfibrozil;Clinical Pharmacokinetics;2023-11-03

3. Comparative analysis of CYP2C8-medidated drug-drug interactions produced by CYP2C8 inhibitors, gemfibrozil versus clopidogrel, focusing on the inhibition of drug distribution in UDP-glucuronosyltransferase prior to oxidation;2023-01-09

4. Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug–Drug–Gene Interaction Predictions;Pharmaceutics;2022-04-22

5. A Quantitative Approach to the Prediction of Drug-Drug Interactions Mediated by Cytochrome P450 2C8 Inhibition;Expert Opinion on Drug Metabolism & Toxicology;2021-11-02